Aug 10, 2026 07:00AM
Aug 4, 2026 07:00AM
Jul 6, 2026 07:00AM
May 20, 2026 07:00AM
Mar 25, 2026 07:00AM
Mar 23, 2026 07:00AM
Oct 15, 2025 07:00AM Algernon Pharmaceuticals changes name to Algernon Health
Oct 15, 2025 07:00AM
Sep 25, 2025 07:00AM
Sep 4, 2025 07:00AM
Sep 4, 2025 07:00AM
May 13, 2025 07:00AM
Jul 16, 2024 08:00AM
Mar 27, 2024 12:04PM Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Nov 22, 2023 07:00AM
Jun 27, 2023 07:00AM
Jan 9, 2023 07:00AM
Dec 5, 2022 07:00AM
Sep 19, 2022 07:00AM
Sep 1, 2022 07:00AM
Jul 18, 2022 08:00AM Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
Feb 23, 2022 07:00AM
Jan 14, 2022 08:15AM
Dec 2, 2021 07:00AM
Nov 24, 2021 07:00AM
Oct 15, 2021 12:00PM
Oct 13, 2021 07:00AM
Oct 8, 2021 07:00AM Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Sep 22, 2021 07:30AM
Sep 20, 2021 07:00AM
Aug 11, 2021 07:00AM
Aug 9, 2021 07:00AM
Jul 6, 2021 08:30AM
Jun 3, 2021 07:00AM
May 17, 2021 07:00AM Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
Apr 26, 2021 08:07AM
Apr 26, 2021 08:00AM
Apr 8, 2021 07:00AM
Mar 31, 2021 08:00AM
Mar 17, 2021 07:00AM
Feb 19, 2021 08:00AM
Feb 1, 2021 07:30AM Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”
Jan 7, 2021 08:00AM
Dec 30, 2020 08:00AM
Dec 17, 2020 08:00AM
Dec 15, 2020 08:15AM
Jun 25, 2020 08:00AM
Jun 4, 2020 12:10PM
May 26, 2020 08:49AM Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19
May 25, 2020 08:00AM

328,148 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All